Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Apraglutide by Ironwood Pharmaceuticals for Short Bowel Syndrome: Likelihood of Approval
Apraglutide is under clinical development by Ironwood Pharmaceuticals and currently in Phase III for Short Bowel Syndrome. According to GlobalData,...
Apraglutide by Ironwood Pharmaceuticals for Short Bowel Syndrome: Likelihood of Approval
Apraglutide is under clinical development by Ironwood Pharmaceuticals and currently in Phase III for Short Bowel Syndrome. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Ironwood Pharmaceuticals's Apraglutide?
Apraglutide is a synthetic peptide commercialized by Ironwood Pharmaceuticals, with a leading Phase III program in Short Bowel Syndrome. According...